依诺肝素滴定用于烧伤患者静脉血栓栓塞预防的单中心经验
滴定性抗Xa因子监测可能不显著增加出血风险,但需更大样本研究确认其对静脉血栓栓塞预防的影响。
要点
- 烧伤患者依诺肝素滴定组与固定剂量组出血事件无显著差异(P = .67)。
- 初始30 mg组70%达目标抗Xa因子水平,初始40 mg组62%达目标。
- 研究提示依诺肝素滴定不显著增加出血风险,需更大样本验证。
核心结论
- 烧伤患者中依诺肝素滴定不显著增加出血风险,但需更大研究确认对静脉血栓栓塞预防的影响。
主要发现
- 总出血事件16例,固定剂量组与滴定组间无显著差异(P = .67)。
- 单变量分析显示出血与未出血患者在人口学特征或合并症方面无差异。
- 初始30 mg的20例中,14例(70%)首次检查达目标抗Xa因子水平,5例(25%)低于治疗范围,1例(5%)高于治疗范围。
- 初始40 mg的39例中,24例(62%)首次检查达目标抗Xa因子水平,9例(23%)低于治疗范围,6例(15%)高于治疗范围。
关键数值与推荐
- 固定剂量方案为依诺肝素30 mg每日两次。
- 滴定方案为基于抗Xa因子指导、每日两次依诺肝素滴定,谷浓度抗Xa因子水平按10 mg间隔调整,在第四或第五剂给药前复测抗Xa因子水平。
- 滴定组起始剂量根据损伤类型、患者特征和肾清除率,按美国创伤外科医师协会指南确定。
临床怎么用
- 烧伤患者可考虑基于抗Xa因子指导的依诺肝素滴定用于静脉血栓栓塞预防,但需更大研究确认其对静脉血栓栓塞预防的影响。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burn-injured patients develop altered metabolic processes, predisposing them to venous thromboembolism and bleeding. Enoxaparin titration for venous thromboembolism prevention in trauma patients is safe, but this approach is not well-defined in burn-injured patients. We hypothesized that titration of enoxaparin in burn patients is safe and does not increase bleeding risk. We compared a fixed dose 30 mg twice-daily enoxaparin dosing regimen to anti-Xa guided, twice-daily enoxaparin titration. Trough anti-Xa levels were measured and adjusted by 10 mg intervals, with repeat anti-Xa levels measured prior to administration of the fourth or fifth dose. The starting dose in the titrated group was determined by injury type, patient characteristics, and renal clearance as per American Association of Surgeons in Trauma guidelines. One hundred and fifty-two patients were included. Ninety-three received fixed dosing, and 59 were titrated by anti-Xa levels. There were 16 total incidents of bleeding but no difference between the two groups (P = .67). Univariate analysis revealed no differences in patient demographics or comorbidities between those with and without bleeding. When comparing dosing trends, 14 of 20 patients (70%) initiated at 30 mg were at goal anti-Xa level on initial check, while 5 (25%) were subtherapeutic, and 1 (5%) was supratherapeutic. Comparatively, 24 of 39 patients (62%) started at 40 mg were at goal anti-Xa level on initial check, while 9 (23%) were subtherapeutic and 6 (15%) were supratherapeutic. We observed that enoxaparin titration does not significantly increase bleeding risk. Larger studies are needed to confirm these findings and determine their effect on venous thromboembolism prevention.
引用
- Vega K, Palumbo M, Cheng K, et al. Enoxaparin Titration for Venous Thromboembolism Prophylaxis in the Burn-Injured Patient-A Single Center Experience. J Burn Care Res. 2025. PMID: 40474547. doi:10.1093/jbcr/iraf104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。